Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data

被引：0
|
作者：
Wolinsky, J. S. [1 ]
Brochet, B. [2 ]
Hartung, H. -P. [3 ,4 ]
Naismith, R. T. [5 ]
Airas, L. [6 ]
Coutant, K. [7 ]
Koendgen, H. [7 ]
Manfrini, M. [7 ]
Mehta, L. [8 ]
Prajapati, K. [9 ]
Kappos, L. [10 ]
机构：
[1] McGovern Med Sch, Houston, TX USA
[2] Univ Bordeaux, Bordeaux, France
[3] Heinrich Heine Univ Dusseldorf, Ctr Neurol & Neuropsychiat, Dusseldorf, Germany
[4] Heinrich Heine Univ Dusseldorf, LVR Klinikum, Dusseldorf, Germany
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Univ Turku, Div Clin Neurosci, Turku, Finland
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] GCE Solut Inc, Amsterdam, Netherlands
[10] Univ Hosp Basel, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
159
引用
收藏
页码：56 / 57
页数：2
相关论文
共 34 条
  • [21] LOW IMMUNOGENICITY IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB: 3-YEAR RESULTS FROM THE RANDOMIZED CONTROLLED PORTION AND OPEN-LABEL FOLLOW-UP OF A PHASE 3 TRIAL
    Bao, M.
    Mallalieu, N. L.
    Stone, J. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 371 - 372
  • [22] A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 2 interim analysis
    Comi, G.
    Bermel, R.
    Bar-Or, A.
    McGinley, M.
    Arnold, D.
    Henry, R.
    Benedict, R.
    Bhargava, P.
    Butzkueven, H.
    Chard, D.
    Gherardi, G.
    Howell, O.
    Lebrun-Frenay, C.
    Leocani, L.
    Kazlauskaite, A.
    Bernasconi, C.
    Montalban, X.
    Sormani, M. P.
    Sellebjerg, F.
    Craveiro, L.
    Lubetzki, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 614 - 615
  • [23] Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
    Rule, S.
    Jurczak, W.
    Jerkeman, M.
    Rusconi, C.
    Trneny, M.
    Offner, F.
    Caballero, D.
    Joao, C.
    Witzens-Harig, M.
    Hess, G.
    Bence-Bruckler, I.
    Cho, S-G
    Thieblemont, C.
    Zhou, W.
    Henninger, T.
    Goldberg, J.
    Vermeulen, J.
    Dreyling, M.
    LEUKEMIA, 2018, 32 (08) : 1799 - 1803
  • [24] Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
    S Rule
    W Jurczak
    M Jerkeman
    C Rusconi
    M Trneny
    F Offner
    D Caballero
    C Joao
    M Witzens-Harig
    G Hess
    I Bence-Bruckler
    S-G Cho
    C Thieblemont
    W Zhou
    T Henninger
    J Goldberg
    J Vermeulen
    M Dreyling
    Leukemia, 2018, 32 : 1799 - 1803
  • [25] Steady-State Pharmacokinetics and Tolerability of Orally Administered Fampridine Sustained-Release 10-mg Tablets in Patients With Multiple Sclerosis: A 2-Week, Open-Label, Follow-Up Study
    Vollmer, Timothy
    Blight, Andrew R.
    Henney, Herbert R., III
    CLINICAL THERAPEUTICS, 2009, 31 (10) : 2215 - 2223
  • [26] Long-term safety data from the extension of the phase III TRANSFORMS study of fingolimod versus interferon beta-1a in relapsing-remitting multiple sclerosis: 4.5 year follow-up
    Hartung, H.
    Barkhof, F.
    Comi, G.
    Montalban, X.
    Pelletier, J.
    Khatri, B.
    Stites, T.
    Kornyeyeva, E.
    Holdbrook, F.
    von Rosensteil, P.
    Collins, W.
    Kappos, L.
    Cohen, J.
    JOURNAL OF NEUROLOGY, 2012, 259 : S70 - S70
  • [27] Long-term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus interferon beta-1a in relapsing-remitting multiple sclerosis: 4.5 year follow-up
    Khatri, B.
    Barkhof, F.
    Comi, G.
    Hartung, H.
    Kappos, L.
    Montalban, X.
    Pelletier, J.
    Stites, T.
    Kornyeyeva, E.
    Holdbrook, F.
    von Rosenstiel, P.
    Cohen, J.
    JOURNAL OF NEUROLOGY, 2012, 259 : S21 - S21
  • [28] Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-3-Year Safety and Efficacy Follow-up
    Dimopoulos, Meletios A.
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Palumbo, Antonio
    San Miguel, Jesus
    Shpilberg, Ofer
    Anderson, Kenneth C.
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen-Nativ, Hila
    Mateos, Maria-Victoria
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Bleickhardt, Eric
    Poulart, Valerie
    Katz, Jessica
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [29] Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial
    Fransson, Per
    Lund, Jo-Asmund
    Damber, Jan-Erik
    Klepp, Olbjorn
    Wiklund, Fredrik
    Fossa, Sophie
    Widmark, Anders
    LANCET ONCOLOGY, 2009, 10 (04): : 370 - 380
  • [30] A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)
    Benedict, Ralph
    Sormani, Maria Pia
    McGinley, Marisa
    Arnold, Douglas
    Bar-Or, Amit
    Bermel, Robert
    Bhargava, Pavan
    Chard, Declan
    Gherardi, Guy
    Henry, Roland
    Howell, Owain
    Lebrun-Frenay, Christine
    Leocani, Letizia
    Lubetzki, Catherine
    Kazlauskaite, Agne
    Kuenzel, Thomas
    Montalban, Xavier
    Sellebjerg, Finn
    Comi, Giancarlo
    Craveiro, Licinio
    Butzkeuven, Helmut
    NEUROLOGY, 2022, 98 (18)
1234